Clinical study on the efficacy and tolerability of a topical regenerative treatment in patients with telogen effluvium and mild androgenetic alopecia.
Stephano CedirianFrancesca BruniF QuadrelliGemma CaroM FortunaAlfredo RossiB M PiracciniMichela Valeria Rita StaracePublished in: Journal of cosmetic dermatology (2023)
Hair loss may change the quality of life since modern society considers hair an essential element in beauty definition. The most common causes of hair loss are androgenetic alopecia (AGA) and telogen effluvium (TE). AGA requires a lifetime use of minoxidil or finasteride (and sometimes they lose efficacy over the years), whereas TE has no standardized therapy available. Our study focuses on a novel topical regenerative preparation that, by mimicking autologous PRP, can safely and efficiently improve hair loss in patients affected by TE and AGA.
Keyphrases
- platelet rich plasma
- cell therapy
- stem cells
- mesenchymal stem cells
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- bone marrow
- prognostic factors
- tissue engineering
- randomized controlled trial
- mass spectrometry
- combination therapy
- molecularly imprinted
- benign prostatic hyperplasia